PROTAGONIST THERAPEUTICS INC's ticker is PTGX and the CUSIP is 74366E102. A total of 142 filers reported holding PROTAGONIST THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 0.34 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $53,849,612 | -38.1% | 3,228,394 | +2.6% | 0.00% | -50.0% |
| Q2 2023 | $86,940,993 | +16.6% | 3,147,755 | -2.9% | 0.00% | 0.0% |
| Q1 2023 | $74,549,739 | +120.6% | 3,241,293 | +4.6% | 0.00% | +100.0% |
| Q4 2022 | $33,796,060 | +36.2% | 3,097,714 | +5.3% | 0.00% | 0.0% |
| Q3 2022 | $24,807,000 | +14.7% | 2,942,767 | +7.6% | 0.00% | 0.0% |
| Q2 2022 | $21,631,000 | -60.8% | 2,734,765 | +17.4% | 0.00% | 0.0% |
| Q1 2022 | $55,176,000 | -31.3% | 2,330,074 | -0.8% | 0.00% | -50.0% |
| Q4 2021 | $80,307,000 | +92.5% | 2,348,166 | -0.2% | 0.00% | +100.0% |
| Q3 2021 | $41,710,000 | -59.4% | 2,353,786 | +2.9% | 0.00% | -66.7% |
| Q2 2021 | $102,686,000 | +85.2% | 2,288,034 | +6.9% | 0.00% | +200.0% |
| Q1 2021 | $55,441,000 | +36.3% | 2,140,547 | +6.1% | 0.00% | 0.0% |
| Q4 2020 | $40,675,000 | +34.0% | 2,017,637 | +30.0% | 0.00% | 0.0% |
| Q3 2020 | $30,352,000 | +21.0% | 1,552,459 | +9.3% | 0.00% | 0.0% |
| Q2 2020 | $25,084,000 | +258.3% | 1,420,361 | +43.3% | 0.00% | – |
| Q1 2020 | $7,000,000 | +0.3% | 991,469 | +0.2% | 0.00% | – |
| Q4 2019 | $6,978,000 | -37.9% | 989,785 | +5.8% | 0.00% | – |
| Q3 2019 | $11,236,000 | +15.9% | 935,542 | +16.9% | 0.00% | – |
| Q2 2019 | $9,694,000 | +10.2% | 800,484 | +14.4% | 0.00% | – |
| Q1 2019 | $8,793,000 | +98.0% | 699,524 | +6.0% | 0.00% | – |
| Q4 2018 | $4,440,000 | -18.7% | 659,780 | +24.4% | 0.00% | – |
| Q3 2018 | $5,458,000 | +57.1% | 530,495 | +2.6% | 0.00% | – |
| Q2 2018 | $3,475,000 | -22.9% | 517,154 | -1.4% | 0.00% | – |
| Q1 2018 | $4,506,000 | -55.1% | 524,458 | +8.7% | 0.00% | – |
| Q4 2017 | $10,037,000 | +59.6% | 482,545 | +35.6% | 0.00% | – |
| Q3 2017 | $6,288,000 | +70.9% | 355,855 | +9.4% | 0.00% | – |
| Q2 2017 | $3,680,000 | -8.4% | 325,395 | +3.8% | 0.00% | – |
| Q1 2017 | $4,016,000 | -41.1% | 313,514 | +1.1% | 0.00% | – |
| Q4 2016 | $6,818,000 | +126.4% | 310,079 | +117.6% | 0.00% | – |
| Q3 2016 | $3,011,000 | – | 142,468 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 2,449,183 | $19,373,000 | 4.95% |
| Bain Capital Life Sciences Investors, LLC | 2,260,572 | $17,881,000 | 2.10% |
| Finepoint Capital LP | 735,126 | $5,815,000 | 2.01% |
| Altium Capital Management LP | 365,100 | $2,888,000 | 1.16% |
| RTW INVESTMENTS, LP | 4,794,499 | $37,924,000 | 0.98% |
| Amitell Capital Pte Ltd | 50,129 | $397,000 | 0.90% |
| COWEN AND COMPANY, LLC | 1,065,724 | $8,430,000 | 0.81% |
| Tri Locum Partners LP | 155,000 | $1,226,000 | 0.50% |
| BVF INC/IL | 1,106,838 | $8,755,000 | 0.42% |
| HighVista Strategies LLC | 46,459 | $367,000 | 0.22% |